Mabwell Sets 30 August Board Meeting to Approve 1H 2026 Interim Results
Bulletin Express
Aug 19
Mabwell (Shanghai) Bioscience Co., Ltd. has scheduled a board meeting for Sunday, 30 August 2026. The agenda includes deliberation and approval of the Group’s interim financial results for the six months ended 30 June 2026, as well as the handling of any additional corporate matters.
The meeting notice, signed by Chairman and Executive Director Dr. Liu Datao, confirms the current Board composition: Executive Directors Mr. Tang Chunshan, Dr. Liu Datao, Dr. Wu Hai, Mr. Hua Jun and Dr. Gui Xun; Independent Non-Executive Directors Mr. Qin Zhengyu, Mr. Zhou Rui, Ms. Li Fan and Ms. Wang Fang.
No further financial figures or operational details were disclosed in the announcement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.